Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis
Authors' conclusion
Measurement of cardiac troponin results in a modest improvement in the prediction of first-onset CVD that may translate into population health benefits if used at scale.
Study context
- Population
- Participants without prior cardiovascular disease (CVD)
- Participants
- 62,150 participants15 cohorts
- Comparison
- Conventional risk factors plus cardiac troponin T (cTnT) or cTnI vs conventional risk factors alone
- Outcome
- First-onset CVD (CHD or stroke)
Methodological details15 cohorts
- 15 cohorts
Pooled result
As reported in the abstract
First-onset CVD
cTnT
8,133
events
cTnI
3,749
events
Hazard ratio (95% CI)
cTnTper 1-SD higher concentration
1.31(1.25–1.37)
cTnIper 1-SD higher concentration
1.26(1.19–1.33)
Per 1-SD higher concentration, as printed
C-index increase (95% CI)
cTnTvs Conventional risk factors
0.015(0.012–0.018)
cTnIvs Conventional risk factors
0.012(0.009–0.015)
Further pooled results
| Outcome | cTnT | cTnI |
|---|---|---|
| Modelled statin therapy after reclassification from intermediate to high risk | ||
| Individuals screened to prevent 1 CVD event | 408 | 473 |
- Modelled statin therapy after reclassification from intermediate to high risk: modelled using incidence rates from 2.1 million UK individuals
Original publication
Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis. J Am Coll Cardiol. Published 15 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →